Tag «serine/threonine kinase inhibitor»

Ocadusertib

It’s only fair to share… Ocadusertib CAS 2382811-41-6 MF C25H25N5O4 MW 459.5 g/mol 5-benzyl-N-[(3S)-7-(3-hydroxy-3-methylbut-1-ynyl)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1H-1,2,4-triazole-3-carboxamide 5-benzyl-N-[(3S)-7-(3-hydroxy-3-methylbut-1-yn-1-yl)-5-methyl-4-oxo-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]-1H-1,2,4-triazole-3-carboxamideserine/threonine kinase inhibitor, LY3871801, R552, LY 3871801, R 552, S53J4A7ME4 Ocadusertib (LY3871801/R552) is an oral, potent, and selective small-molecule RIPK1 inhibitor developed by Rigel Pharmaceuticals and Eli Lilly for autoimmune and inflammatory diseases. It is currently in Phase 2 clinical trials for treating moderate-to-severe rheumatoid arthritis. ACR …

Nacresertib

It’s only fair to share… Nacresertib CAS 2629977-59-7 MF C22H26N4O4, 410.5 g/mol N-[2-(4-hydroxy-4-methylcyclohexyl)-6-methoxyindazol-5-yl]-6-methyl-1-oxidopyridin-1-ium-2-carboxamide 2-({2-[(1r,4r)-4-hydroxy-4-methylcyclohexyl]-6-methoxy-2H-indazol-5-yl}carbamoyl)-6-methylpyridine1-oxideserine/threonine kinase inhibitor, MB3QBD4BE7, SYN compound 001 [WO2021057785] https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021057785&_cid=P20-MLN614-09477-1 Example 1: Synthesis of Compound 001 ynthesis of compound 001, namely 2-((2-(trans-4-hydroxy-cis-4-methylcyclohexyl)-6-methoxy-2H-indazol-5-yl)carbamoyl)-6-methylpyridine 1-oxide [0133] [0134]Cesium carbonate (985 mg) was added to 5 mL of a DMF solution containing compound 12 (300 mg) and compound 5 …